Pyxis Oncology (PYXS)
(Delayed Data from NSDQ)
$2.25 USD
-0.07 (-3.02%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.24 -0.01 (-0.44%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PYXS 2.25 -0.07(-3.02%)
Will PYXS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PYXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PYXS
Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross?
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
PYXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
Other News for PYXS
The technical outlook for PYXS is unchanged after it falls 3.02% on September 19
PYXS forms Upper Bollinger Band Walk on September 18
Is PYXS building bullish momentum? Pocket Pivot shows up after rocketing 7.8%
Pyxis Oncology (PYXS) Gets a Buy from H.C. Wainwright
Golden Cross appears for PYXS after 7.89% move